Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 1—January 2017
Research

Sequelae and Other Conditions in Ebola Virus Disease Survivors, Sierra Leone, 2015

Hamish MohammedComments to Author , Alren O. Vandy, Rebecca Stretch, David Otieno, Mukesh Prajapati, Mauricio Calderon, and Mohamed Vandi
Author affiliations: Public Health England, London, UK (H. Mohammed); World Health Organization, Kenema, Sierra Leone (H. Mohammed, A.O. Vandy, R. Stretch, D. Otieno, M. Prajapati); World Health Organization, Freetown, Sierra Leone (M. Calderon); District Health Management Team, Kenema, Sierra Leone (M. Vandi)

Main Article

Table

Characteristics reported at 621 attendances by 115 survivors of laboratory-confirmed Ebola virus disease attending the Survivor Clinic at Kenema Government Hospital, Sierra Leone, 2014—2015*

Characteristic Overall† Fever‡
p value§
Yes No
Sex
M 187 (30.7) [27.1–34.4] 123 (30.2) 64 (25.1) 0.309
F
423 (69.3) [65.6–72.9]
284 (69.8)
191 (74.9)
Ref
Duration since discharge, d
4–144 131 (21.1) [18.1–24.5] 61 (14.8) 107 (42.1) <0.001
145–254 134 (21.6) [18.5–25.0] 96 (23.4) 69 (27.2) <0.001
255–358 221 (35.6) [31.9–39.5] 125 (30.4) 41 (16.1) 0.321
359–504
134 (21.6) [18.5–25.0]
129 (31.4)
37 (14.6)
Ref
Age, y
<18 153 (25.0) [21.7–28.5] 109 (26.4) 39 (15.1) Ref
18–28 148 (24.1) [20.9–27.7] 86 (20.8) 52 (20.1) 0.178
29–35 153 (25.0) [21.7–28.5] 142 (34.4) 110 (42.5) 0.025
36–70 159 (25.9) [22.6–29.6] 76 (18.4) 58 (22.4) 0.010
Median (range)
30.0 (0.25–70.00)
30.0 (0.25–70.00)
33.0 (3–70.00)
0.001
Signs and symptoms¶
Joint pain 187 (30.1) [26.6–33.8] 113 (29.5) 74 (31.1) 0.627
Myalgia 269 (43.3) [39.5–47.3] 165 (43.1) 104 (43.7) 0.874
Cough 201 (32.4) [28.8–36.2] 171 (44.7) 30 (12.6) <0.001
Weakness 37 (6.0) [4.3–8.1] 27 (7.1) 10 (4.2) 0.097
Dizziness 89 (14.3) [11.8–17.3] 55 (14.4) 34 (14.3) 0.915
Rash 32 (5.2) [3.7–7.2] 20 (5.2) 12 (5.0) 0.903
Itching 49 (7.9) [6.0–10.3] 24 (6.3) 25 (10.5) 0.028
Blurred vision 19 (3.1) [2.0–4.8] 8 (2.1) 11 (4.6) 0.034
Vision loss 0 0 0 NA
Eye discharge 12 (1.9) [1.1–3.4] 5 (1.3) 7 (2.9) 0.097
Poor vision 15 (2.4) [1.5–4.0] 6 (1.6) 9 (3.8) 0.043
Eye pain 10 (1.6) [0.9–3.0] 7 (1.8) 3 (1.3) 0.837
Eye itch 13 (2.1) [1.2–3.6] 6 (1.6) 7 (2.9) 0.113
Eye irritation 9 (1.4) [0.8–2.8] 8 (2.1) 1 (0.4) 0.119
Eye problems 51 (8.2) [6.3–10.7] 29 (7.6) 22 (9.2) 0.205
Headache 392 (63.1) [59.2–66.8] 272 (71.0) 120 (50.4) <0.001
Diarrhea 17 (2.7) [1.7–4.4] 14 (3.7) 3 (1.3) 0.116
Vomiting 53 (8.5) [6.6–11.0] 44 (11.5) 9 (3.8) 0.010
Insomnia 89 (14.3) [11.8–17.3] 50 (13.1) 39 (16.4) 0.370
Chest burn 35 (5.6) [4.1–7.8] 20 (5.2) 15 (6.3) 0.562
Chest pain 31 (5.0) [3.5–7.0] 13 (3.4) 18 (7.6) 0.044
Abdominal pain 157 (25.3) [22.0–28.9] 102 (26.6) 55 (23.1) 0.620
Appetite loss 149 (24.0) [20.8–27.5] 104 (27.2) 45 (18.9) 0.028
Depression 6 (1.0) [0.4–2.1] 3 (0.8) 3 (1.3) 0.759
Anxiety 20 (3.2) [2.1–4.9] 7 (1.8) 13 (5.5) 0.014
Mental disorder 2 (0.3) [0.1–1.3] 2 (0.5) 0 NA
Palpitation 42 (6.8) [5.0–9.0] 23 (6.0) 19 (8.0) 0.223
Jaundice 1 (0.2) [0.0–1.1] 1 (0.3) 0 NA
Hiccups 0 0 0 NA
Deafness 4 (0.6) [0.2–1.7] 1 (0.3) 3 (1.3) 0.218
Hearing loss 3 (0.5) [0.2–1.5] 1 (0.3) 2 (0.8) 0.350
Amenorrhea 31 (7.3) [5.2–10.2] 16 (6.3) 15 (8.8) 0.222
Erectile dysfunction 6 (3.2) [1.4–7.0] 1 (0.8) 5 (7.8) 0.047

*Within each cross-tabulation, because of missing data, the sum of the component cells may be less than the total number of attendances. Where a zero cell was reported in the cross-tabulation with fever, no p value is reported. NA, not applicable; Ref, reference category.
†All values are no. (%) [95% CI] unless indicated otherwise indicated.
‡All values are no. (%) unless otherwise indicated.
§p values are from univariate generalized estimating equations logistic regression analysis.
¶ Amenorrhea was recorded only for women (age range 15–40 years) and erectile dysfunction only for men (age range 24–35 years). Chest burn is a local term for heartburn.

Main Article

Page created: December 14, 2016
Page updated: December 14, 2016
Page reviewed: December 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external